Posted inCardiology Clinical Updates news Specialties
Volenrelaxin in HFpEF: Unexpected Worsening of Congestion Despite Improvements in Left Atrial Function
This phase 2 trial shows that volenrelaxin, a long-acting relaxin analog, failed to improve overall congestion or kidney function in HFpEF patients and was linked to worsening congestion and safety signals, despite modest left atrial function improvement at low dose.